New study aims to match pancreatic cancer patients with best chemo
NCT ID NCT04469556
First seen Feb 23, 2026 · Last updated Jun 20, 2026 · Updated 15 times
Summary
This phase 2 trial tested two standard chemotherapy regimens, Folfirinox and Gemcitabine/nab-paclitaxel, in 150 patients with untreated metastatic pancreatic cancer. The goal was to see which works better and to use lab tests to personalize treatment. The study is complete, and results may help guide future therapy choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Agency Vancouver
Vancouver, British Columbia, V5Z 1L8, Canada
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwell Health
New Hyde Park, New York, 11042, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2N9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Folfirinox and Gemcitabine/nab-paclitaxel (chemotherapy)
What this could lead to
If successful, this could help doctors choose the best chemotherapy for each patient with advanced pancreatic cancer, potentially improving survival.
What could go wrong
This is a mid-stage trial with 150 participants, so results may not apply to everyone. Chemotherapy has significant side effects, and the study may not show a clear benefit for either drug.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.